XGN

Exagen Inc. (XGN) - Q3 2024 10-Q Summary

Business Context and Reporting Period

Exagen Inc. is a commercial-stage diagnostics company focused on autoimmune disease decision-making, primarily through its AVISE® CTD test. This report covers the quarterly period ended September 30, 2024. The company is classified as a non-accelerated filer, smaller reporting company, and emerging growth company.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline (Q3): Revenue decreased 6.8% year-over-year to $12.5 million. This was primarily driven by a $1.2 million reduction in revenue due to adjustments, including a $0.9 million reserve for accounts receivable related to AVISE® CTD testing and a $0.3 million reversal for coding discrepancies. Excluding these adjustments, revenue would have increased slightly due to improved Average Selling Price (ASP).
• Volume Decline: The number of AVISE® CTD tests delivered declined approximately 6% in Q3 and 13% year-to-date compared to 2023, attributed to seasonal factors and adjustments to revenue cycle management initiatives.
• Expense Reduction: Selling, General, and Administrative (SG&A) expenses decreased by $1.2 million (10.7%) in Q3 and $4.0 million (11.5%) YTD, largely due to reduced headcount and lower professional service and legal expenses.
• Improved Loss Profile: Net loss narrowed significantly on a YTD basis ($11.4 million vs. $18.1 million in 2023) due to cost containment and revenue adjustments.

Outlook, Risks, and Management Commentary

• Product Pipeline: Management plans to incorporate new T-Cell Biomarkers (TC4d, TIgG, TIgM) and RA Sub-Profile Biomarkers into the AVISE® CTD test by the end of 2024. These additions aim to improve diagnostic sensitivity for lupus and seronegative rheumatoid arthritis, potentially increasing ASP and revenue.
• Liquidity: The company holds $22.0 million in cash and cash equivalents. Management believes existing resources are sufficient to fund operations for at least the next 12 months. However, the company has an accumulated deficit of $290.6 million and expects to continue incurring losses.
• Debt Covenants: The company is in compliance with its Amended Loan Agreement with Innovatus. The agreement requires maintaining a minimum cash balance of $2.0 million and has revenue covenants that are waived if the company maintains cash equal to 50% of the loan principal.
• Legal Contingencies: A qui tam lawsuit regarding historical specimen processing arrangements was partially settled with the DOJ for $0.7 million in October 2023. However, the relator's complaint remains pending, and the company intends to vigorously defend against it.
• Reimbursement Risks: Revenue is heavily dependent on third-party payors. The company faces challenges with commercial payor claim processing and denials. A Local Coverage Determination (LCD) for the AVISE® Lupus test with Medicare remains pending.

Investor Verification Checklist

• Revenue Adjustments: Verify the nature and permanence of the $1.2 million revenue reduction in Q3 related to accounts receivable reserves and coding reversals.
• Test Volume Trends: Monitor the 6% Q3 and 13% YTD decline in AVISE® CTD test volumes to determine if this is a temporary seasonal effect or a structural shift in demand.
• Product Launch Timeline: Confirm the end-of-2024 launch schedule for the T-Cell and RA Sub-Profile biomarkers and their expected impact on Average Selling Price (ASP).
• Cash Burn Rate: Assess the sustainability of the $22.0 million cash balance given the $13.6 million operating cash outflow YTD and the need for potential future financing.
• Legal Exposure: Track the status of the pending qui tam lawsuit motions to understand potential future liabilities beyond the $0.7 million settlement.